Loading...
Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
OBJECTIVES: This study was conducted to evaluate the efficacy and safety of apatinib in advanced NSCLC patients with EGFR wild-type who have failed more than second-line chemotherapy. MATERIALS AND METHODS: We retrospectively analyzed patients with EGFR wild-type advanced NSCLC who were treated with...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5805545/ https://ncbi.nlm.nih.gov/pubmed/29467959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23612 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|